Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs

Reuters

2025/07/25

Janux <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs

Janux Therapeutics Inc. recently held an R&D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554735671"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554735671\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554735671?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-25 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554735671","market":"us","top_or_hot":-1,"title":"Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils R&amp;D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Janux Therapeutics Inc. recently held an R&amp;D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&amp;I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-25 05:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils R&amp;D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Janux Therapeutics Inc. recently held an R&amp;D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&amp;I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JANX","symbol_name":"Janux Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL3kL1Hg:1","article_id":"2554735671","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554735671","pubTimestamp":1753393135,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Janux Therapeutics Inc. recently held an R&D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer , and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative arti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JANX":"Janux Therapeutics, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Janux Therapeutics推出研发演示，重点介绍癌症和自身免疫性疾病项目的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JANX":0.9},"content_text":"Janux Therapeutics Unveils R&D Presentation Highlighting Advancements in Cancer and Autoimmune Disease Programs\n    \n\n        Janux Therapeutics Inc. recently held an R&D Day presentation, highlighting multiple near-term, high-value opportunities in cancer and inflammation and immunology (I&I). Their clinical programs include JANX007, currently in Phase 1b dose expansion trials for metastatic castration-resistant prostate cancer (mCRPC), and JANX008, undergoing Phase 1a evaluation for various solid tumor settings. The development pipeline features promising candidates such as PSMAxCD28-TRACIr, with an IND anticipated in the first half of 2026, and TROP2xCD3-TRACTr, with IND-enabling activities planned for the second half of 2025. Additionally, the CD19-ARM program presents potential in autoimmune diseases and hematologic oncology. The company reports a robust cash position of $1.01 billion as of March 2025, ensuring financial runway through significant clinical milestones. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}